Who we are

We have been transforming lives in healthcare since 1885. Our approximately 54,300 employees in 130 markets create value through innovation by infusing long-term, sustainable thinking into our Human Pharma and Animal Health units.

We acknowledge the deep and complex ways the lives of humans and animals are interconnected and work on breakthrough therapies and co-create solutions that help millions of people worldwide live longer, healthier lives.

Planning certainty is the foundation for innovation

Reliable framework conditions secure investment, progress and supply in Germany.

[Half-year 2026: Growth and pipeline progress](/content/about-us/who-we-are/our-half-year-financial-results-2026 "Our half-year financial results 2026"/index.html)

Half-year 2026: Growth and pipeline progress

Boehringer Ingelheim reports first-half 2026 sales growth, driven by JARDIANCE® and new product launches in the U.S.

[Teaming up to strengthen our supply chain.](/content/about-us/who-we-are/better-together-teaming-strengthen-our-supply-chain "Better together: Teaming up to strengthen our supply chain"/index.html)

Teaming up to strengthen our supply chain.

How international teamwork and collaboration across cultures helps U.S. patients.

Boehringer reports first-half 2026 sales growth, driven by JARDIANCE® and product launches

July 15, 2026

[Boehringer delivers on late-stage pipeline with two key launches, grows sales by 7.3%](/content/about-us/who-we-are/2025-pipeline-key-product-launches-sales-growth "2025 pipeline key product launches sales growth"/index.html)

March 25, 2026

Boehringer delivers on late-stage pipeline with two key launches, grows sales by 7.3 %

References